| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
AstraZeneca's diabetes drug wins approval for heart failure treatment in Japan
StockMarketWire.com
|
Pharmaceutical giant AstraZeneca said its diabetes drug Forxiga had been approved in Japan to treat patients with chronic heart failure.
The approval was based on positive results from the DAPA-HF phase 3 trial published in The New England Journal of Medicine.
Additionally, Forxiga was currently being tested for heart failure patients with preserved ejection fraction in the DELIVER phase 3 trial with data readout anticipated in the second half of 2021, the company said.
Story provided by StockMarketWire.com
|
|
|
|
|
|
